All In Biotech

Investigational drug · Phase 2

CGT4859

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Intrahepatic Cholangiocarcinoma (Icc), Cholangiocarcinoma, Other Solid Tumors, Adult.

Phase 2

Last checked: Nov 19, 2026Latest source record: Apr 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "CGT4859"

First trial start

2025

Jan 22, 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "CGT4859", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Intrahepatic Cholangiocarcinoma (Icc)
  • Cholangiocarcinoma
  • Other Solid Tumors, Adult
  • FGFR2 Gene Fusion/Rearrangement
  • FGFR2 Gene Amplification
  • FGFR2 Gene Short Variants
  • FGFR3 Gene Fusion/Rearrangement
  • FGFR3 Gene Amplification
  • FGFR3 Gene Short Variants
  • FGFR2 Genetic Alterations

Approved drugs for the same conditions: Oncology · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "CGT4859" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Intrahepatic Cholangiocarcinoma (Icc)

  • tinengotinibTT-00420Phase 36 trials

    TransThera Sciences (Nanjing), Inc. · Prostate Cancer (CRPC), Cholangiocarcinoma, Hepatocellular Carcinoma (HCC)

  • ICP-192Phase 21 trial

    Beijing InnoCare Pharma Tech Co., Ltd. · Intrahepatic Cholangiocarcinoma (ICC)

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.